• 1
    Kronenberg F, Utermann G. Lipoprotein(a) – resurrected by genetics. J Intern Med 2013; 273: 630.
  • 2
    Utermann G, Menzel HJ, Kraft HG, Duba HC, Kemmler HG, Seitz C. Lp(a) glycoprotein phenotypes: inheritance and relation to Lp(a)-lipoprotein concentrations in plasma. J Clin Invest 1987; 80: 45865.
  • 3
    Lackner C, Boerwinkle E, Leffert CC, Rahmig T, Hobbs HH. Molecular basis of apolipoprotein (a) isoform size heterogeneity as revealed by pulsed-field gel electrophoresis. J Clin Invest 1991; 87: 215361.
  • 4
    Kraft HG, Köchl S, Menzel HJ, Sandholzer C, Utermann G. The apolipoprotein(a) gene: a transcribed hypervariable locus controlling plasma lipoprotein(a) concentration. Hum Genet 1992; 90: 22030.
  • 5
    Sandholzer C, Saha N, Kark JD et al. Apo(a) isoforms predict risk for coronary heart disease: a study in six populations. Arterioscler Thromb 1992; 12: 121426.
  • 6
    Erqou S, Kaptoge S, Perry PL et al. Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality. JAMA 2009; 302: 41223.
  • 7
    Erqou S, Thompson A, Di Angelantonio E et al. Apolipoprotein(a) isoforms and the risk of vascular disease: systematic review of 40 studies involving 58,000 participants. J Am Coll Cardiol 2010; 55: 21607.
  • 8
    Clarke R, Peden JF, Hopewell JC et al. Genetic variants associated with Lp(a) lipoprotein level and coronary disease. N Engl J Med 2009; 361: 251828.
  • 9
    Kronenberg F. Lipoprotein(a): there's life in the old dog yet. Circulation 2014; 129: 61921.
  • 10
    Raal FJ, Santos RD, Blom DJ et al. Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial. Lancet 2010; 375: 9981006.
  • 11
    Desai NR, Kohli P, Giugliano RP et al. AMG145, a monoclonal antibody against proprotein convertase subtilisin kexin type 9, significantly reduces lipoprotein(a) in hypercholesterolemic patients receiving statin therapy: an analysis from the LDL-C Assessment with Proprotein Convertase Subtilisin Kexin Type 9 Monoclonal Antibody Inhibition Combined with Statin Therapy (LAPLACE)-Thrombolysis in Myocardial Infarction (TIMI) 57 trial. Circulation 2013; 128: 9629.
  • 12
    Cannon CP, Shah S, Dansky HM et al. Safety of anacetrapib in patients with or at high risk for coronary heart disease. N Engl J Med 2010; 363: 240615.
  • 13
    Jaeger BR, Richter Y, Nagel D et al. Longitudinal cohort study on the effectiveness of lipid apheresis treatment to reduce high lipoprotein(a) levels and prevent major adverse coronary events. Nat Clin Pract Cardiovasc Med 2009; 6: 22939.
  • 14
    Leebmann J, Roseler E, Julius U et al. Lipoprotein apheresis in patients with maximally tolerated lipid lowering therapy, Lp(a)-hyperlipoproteinemia and progressive cardiovascular disease: prospective observational multicenter study. Circulation 2013; 128: 256776.
  • 15
    Safarova MS, Ezhov MV, Afanasieva OI et al. Effect of specific lipoprotein(a) apheresis on coronary atherosclerosis regression assessed by quantitative coronary angiography. Atheroscler Suppl 2013; 14: 939.
  • 16
    Hopewell JC, Seedorf U, Farrall M et al. Impact of Lp(a) levels and apolipoprotein(a) isoform size on risk of coronary heart disease. J Intern Med (in press).
  • 17
    Kronenberg F, Kronenberg MF, Kiechl S et al. Role of lipoprotein(a) and apolipoprotein(a) phenotype in atherogenesis: prospective results from the Bruneck Study. Circulation 1999; 100: 115460.
  • 18
    Kamstrup PR, Tybjaerg-Hansen A, Steffensen R, Nordestgaard BG. Genetically elevated lipoprotein(a) and increased risk of myocardial infarction. JAMA 2009; 301: 23319.
  • 19
    Kraft HG, Lingenhel A, Köchl S et al. Apolipoprotein(a) Kringle IV repeat number predicts risk for coronary heart disease. Arterioscler Thromb Vasc Biol 1996; 16: 7139.
  • 20
    Kronenberg F. Causes and consequences of lipoprotein(a) abnormalities in kidney disease. Clin Exp Nephrol (in press).
  • 21
    Mora S, Kamstrup PR, Rifai N, Nordestgaard BG, Buring JE, Ridker PM. Lipoprotein(a) and risk of type 2 diabetes. Clin Chem 2010; 56: 125260.
  • 22
    Kamstrup PR, Nordestgaard BG. Lipoprotein(a) levels, isoform size, and risk of type 2 diabetes: a Mendelian Randomisation study. Lancet Diabetes Endocrinol 2013; 1: 2207.
  • 23
    Ye Z, Haycock PC, Gurdasani D et al. The association between circulating lipoprotein(a) and type 2 diabetes: is it causal? Diabetes 2014; 63: 33242.
  • 24
    Lamina C, Kronenberg F. The mysterious lipoprotein(a) is still good for a surprise. Lancet Diabetes Endocrinol 2013; 1: 1702.